NEW YORK (360Dx) – Lunaphore Technologies has partnered with Vitro to develop in situ hybridization (ISH) protocols for RNA and DNA targets in tissue, the companies announced today.
Under the terms of the deal, the partners will develop the protocols using Vitro reagents on Lunaphore's microfluidics-based rapid autostaining platform, which is currently in the prototype stage. Additional terms were not disclosed.
"Vitro can provide access to key know-how as well as quality ISH reagents, while Lunaphore has a unique automation technology," Lunaphore CEO Ata Tuna Ciftlik said in a statement. "While Lunaphore has so far focused on immunohistology, ISH applications have always remained strategically important."